{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:12:35Z","timestamp":1794471155406,"version":"4.9.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamaophthalmol.2019.5540","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T16:31:13Z","timestamp":1578587473000},"page":"244","source":"Crossref","is-referenced-by-count":81,"title":["Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease"],"prefix":"10.1001","volume":"138","author":[{"given":"Peter J.","family":"Kertes","sequence":"first","affiliation":[{"name":"The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan J.","family":"Galic","sequence":"additional","affiliation":[{"name":"Montreal Retina Institute, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Greve","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"Department of Ophthalmology & Visual Sciences, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Williams","sequence":"additional","affiliation":[{"name":"Calgary Retina Consultants, Calgary, Alberta, Canada"},{"name":"Department of Surgery, Section Ophthalmology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Baker","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Canada Inc, Dorval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Lahaie","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Canada Inc, Dorval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sheidow","sequence":"additional","affiliation":[{"name":"Ivey Eye Institute, London, Ontario, Canada"},{"name":"Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi190093r1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"14","key":"eoi190093r2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi190093r3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi190093r4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi190093r5","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi190093r6","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"eoi190093r7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/OPTH","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey.","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"eoi190093r8","first-page":"1001","article-title":"Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.","volume":"9","author":"Agarwal","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"eoi190093r9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","article-title":"Ranibizumab according to need: a treatment for age-related macular degeneration.","volume":"143","author":"Spaide","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi190093r10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/jcm4051079","article-title":"Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? or losing?","volume":"4","author":"Stewart","year":"2015","journal-title":"J Clin Med"},{"issue":"1","key":"eoi190093r11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12886-017-0451-1","article-title":"24-Month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.","volume":"17","author":"Vardarinos","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"eoi190093r12","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results.","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi190093r13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study.","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"eoi190093r14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bjophthalmol-2017-310822","article-title":"Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.","volume":"102","author":"Wykoff","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"eoi190093r15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","article-title":"A systematic review to assess the \u201ctreat-and-extend\u201d dosing regimen for neovascular age-related macular degeneration using ranibizumab.","volume":"31","author":"Rufai","year":"2017","journal-title":"Eye (Lond)"},{"issue":"8","key":"eoi190093r16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration.","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"issue":"6","key":"eoi190093r17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration.","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi190093r18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92?976 ranibizumab injections: report 1: visual acuity.","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi190093r19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study.","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi190093r20","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1111\/aos.2017.95.issue-1","article-title":"Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 month study.","volume":"95","author":"Hatz","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"eoi190093r21","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1097\/IAE.0000000000000978","article-title":"Near vision outcome in patients with age-related macular degeneration treated with aflibercept.","volume":"36","author":"Epstein","year":"2016","journal-title":"Retina"},{"issue":"2","key":"eoi190093r22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/IAE.0000000000000691","article-title":"Retrospective review of Lucentis \u201ctreat and extend\u201d patterns and outcomes in age-related macular degeneration.","volume":"36","author":"Chen","year":"2016","journal-title":"Retina"},{"issue":"5","key":"eoi190093r23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/IAE.0000000000000814","article-title":"Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20\/40 using a treat-and-extend regime.","volume":"36","author":"Rahimy","year":"2016","journal-title":"Retina"},{"issue":"1","key":"eoi190093r24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","article-title":"Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi190093r25","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/eye.2015.87","article-title":"Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.","volume":"29","author":"Homer","year":"2015","journal-title":"Eye (Lond)"},{"issue":"7","key":"eoi190093r26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/IAE.0000000000000902","article-title":"Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol.","volume":"36","author":"Wickremasinghe","year":"2016","journal-title":"Retina"},{"issue":"3","key":"eoi190093r27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/bjophthalmol-2014-305514","article-title":"Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data.","volume":"99","author":"Barthelmes","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi190093r28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi190093r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/AJOCT-2-2018","article-title":"Treat and extend dosing regimen with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.","volume":"1","author":"Wai","year":"2018","journal-title":"Am J Ophthalmic Clin Trials"},{"issue":"78","key":"eoi190093r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-Related Choroidal Neovascularisation (IVAN).","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"issue":"6","key":"eoi190093r31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian Treat-and-Extend Analysis Trial With Ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian Treat-and-Extend Analysis Trial With Ranibizumab Study.","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi190093r32","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"eoi190093r33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi190093r34","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration.","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi190093r35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial.","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"eoi190093r36","unstructured":"GilliesMC, AlexP, HunyorAP, . Development of macular atrophy in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab or aflibercept using a treat-and-extend regimen: preliminary results from the RIVAL study, a randomized clinical trial. RANZCO 2018 [abstract 89]. https:\/\/ranzcoabstracts.com\/abstract\/development-of-macular-atrophy-in-patients-with-neovascular-age-related-macular-degeneration-namd-treated-with-ranibizumab-or-aflibercept-using-a-treat-and-extend-regimen-primary-results-from-the\/. Published 2018. Accessed May 22, 2019."}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2758418\/jamaophthalmology_kertes_2020_oi_190093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T05:00:02Z","timestamp":1613451602000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2758418"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5540","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}